Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + S-1
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of irinotecan, a topoisomerase I inhibitor, and S-1, an oral fluoropyrimidine derivative. This combination works synergistically as irinotecan induces arrest at S/G2/M phase while 5-FU (the main metabolite of S-1) induces S phase arrest. It has shown efficacy in treating advanced colorectal cancer and has been studied in non-small cell lung cancer.
- Brand names
- CamptosarCamptoTS-One
- Other names
- camptothecin 11camptothecin11camptothecin-11irinotecan hydrochloride + S-1
02
Targets
TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on irinotecan + S-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + S-1.